Up-front polytherapy for ALK-positive lung cancer
作者： Bingying Zhou , Adrienne D Cox
DOI: 10.1038/NM.3942
关键词:
摘要: A new study identifies the RAS-MAPK pathway to be an Achilles' heel of EML4-ALK fusion-positive lung cancer and suggests that up-front combination therapy directed against both pathways can achieve sustained suppression tumor growth.
nature.com
sci-hub.se 参考文章(9)
Adam S Crystal, Alice T Shaw, Lecia V Sequist, Luc Friboulet, Matthew J Niederst, Elizabeth L Lockerman, Rosa L Frias, Justin F Gainor, Arnaud Amzallag, Patricia Greninger, Dana Lee, Anuj Kalsy, Maria Gomez-Caraballo, Leila Elamine, Emily Howe, Wooyoung Hur, Eugene Lifshits, Hayley E Robinson, Ryohei Katayama, Anthony C Faber, Mark M Awad, Sridhar Ramaswamy, Mari Mino-Kenudson, A John Iafrate, Cyril H Benes, Jeffrey A Engelman, None, Patient-derived models of acquired resistance can identify effective drug combinations for cancer Science. ,vol. 346, pp. 1480- 1486 ,(2014) , 10.1126/SCIENCE.1254721
D. Ross Camidge, William Pao, Lecia V. Sequist, Acquired resistance to TKIs in solid tumours: learning from lung cancer Nature Reviews Clinical Oncology. ,vol. 11, pp. 473- 481 ,(2014) , 10.1038/NRCLINONC.2014.104
Bengt Hallberg, Ruth H. Palmer, Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology Nature Reviews Cancer. ,vol. 13, pp. 685- 700 ,(2013) , 10.1038/NRC3580
Ahmed A. Samatar, Poulikos I. Poulikakos, Targeting RAS–ERK signalling in cancer: promises and challenges Nature Reviews Drug Discovery. ,vol. 13, pp. 928- 942 ,(2014) , 10.1038/NRD4281
Frederick H. Wilson, Cory M. Johannessen, Federica Piccioni, Pablo Tamayo, Jong Wook Kim, Eliezer M. Van Allen, Steven M. Corsello, Marzia Capelletti, Antonio Calles, Mohit Butaney, Tanaz Sharifnia, Stacey B. Gabriel, Jill P. Mesirov, William C. Hahn, Jeffrey A. Engelman, Matthew Meyerson, David E. Root, Pasi A. Jänne, Levi A. Garraway, A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell. ,vol. 27, pp. 397- 408 ,(2015) , 10.1016/J.CCELL.2015.02.005
Ryohei Katayama, Christine M. Lovly, Alice T. Shaw, Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine Clinical Cancer Research. ,vol. 21, pp. 2227- 2235 ,(2015) , 10.1158/1078-0432.CCR-14-2791
J Tanizaki, I Okamoto, K Takezawa, K Sakai, K Azuma, K Kuwata, H Yamaguchi, E Hatashita, K Nishio, P A Janne, K Nakagawa, Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells British Journal of Cancer. ,vol. 106, pp. 763- 767 ,(2012) , 10.1038/BJC.2011.586
Rebecca S. Heist, Jeffrey A. Engelman, SnapShot: Non-Small Cell Lung Cancer Cancer Cell. ,vol. 21, ,(2012) , 10.1016/J.CCR.2012.03.007
Gorjan Hrustanovic, Victor Olivas, Evangelos Pazarentzos, Asmin Tulpule, Saurabh Asthana, Collin M Blakely, Ross A Okimoto, Luping Lin, Dana S Neel, Amit Sabnis, Jennifer Flanagan, Elton Chan, Marileila Varella-Garcia, Dara L Aisner, Aria Vaishnavi, Sai-Hong I Ou, Eric A Collisson, Eiki Ichihara, Philip C Mack, Christine M Lovly, Niki Karachaliou, Rafael Rosell, Jonathan W Riess, Robert C Doebele, Trever G Bivona, RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nature Medicine. ,vol. 21, pp. 1038- 1047 ,(2015) , 10.1038/NM.3930